ID   KPYR_HUMAN              Reviewed;         574 AA.
AC   P30613; O75758; P11973;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   10-MAY-2017, entry version 204.
DE   RecName: Full=Pyruvate kinase PKLR;
DE            EC=2.7.1.40;
DE   AltName: Full=Pyruvate kinase 1;
DE   AltName: Full=Pyruvate kinase isozymes L/R;
DE   AltName: Full=R-type/L-type pyruvate kinase;
DE   AltName: Full=Red cell/liver pyruvate kinase;
GN   Name=PKLR; Synonyms=PK1, PKL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PKRD MET-384.
RX   PubMed=1896471; DOI=10.1073/pnas.88.18.8218;
RA   Kanno H., Fujii H., Hirono A., Miwa S.;
RT   "cDNA cloning of human R-type pyruvate kinase and identification of a
RT   single amino acid substitution (Thr384-->Met) affecting enzymatic
RT   stability in a pyruvate kinase variant (PK Tokyo) associated with
RT   hereditary hemolytic anemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:8218-8221(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3126495; DOI=10.1073/pnas.85.6.1792;
RA   Tani K., Fujii H., Nagata S., Miwa S.;
RT   "Human liver type pyruvate kinase: complete amino acid sequence and
RT   the expression in mammalian cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1792-1795(1988).
RN   [3]
RP   SEQUENCE REVISION TO 130 AND 232.
RA   Kanno H.;
RL   Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1445295; DOI=10.1016/0006-291X(92)91086-6;
RA   Kanno H., Fujii H., Miwa S.;
RT   "Structural analysis of human pyruvate kinase L-gene and
RT   identification of the promoter activity in erythroid cells.";
RL   Biochem. Biophys. Res. Commun. 188:516-523(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-506.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM R-TYPE).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 470-574.
RX   PubMed=3566732; DOI=10.1016/0006-291X(87)91372-6;
RA   Tani K., Fujii H., Tsutsumi H., Sukegawa J., Toyoshima K.,
RA   Yoshida M.C., Noguchi T., Tanaka T., Miwa S.;
RT   "Human liver type pyruvate kinase: cDNA cloning and chromosomal
RT   assignment.";
RL   Biochem. Biophys. Res. Commun. 143:431-438(1987).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 365-431, AND VARIANT PKRD PHE-368.
RX   PubMed=8476433; DOI=10.1006/bbrc.1993.1379;
RA   Kanno H., Fujii H., Tsujino G., Miwa S.;
RT   "Molecular basis of impaired pyruvate kinase isozyme conversion in
RT   erythroid cells: a single amino acid substitution near the active site
RT   and decreased mRNA content of the R-type PK.";
RL   Biochem. Biophys. Res. Commun. 192:46-52(1993).
RN   [9]
RP   REVIEW ON VARIANTS.
RX   PubMed=8664896;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:1<1::AID-HUMU1>3.0.CO;2-H;
RA   Beutler E., Baronciani L.;
RT   "Mutations in pyruvate kinase.";
RL   Hum. Mutat. 7:1-6(1996).
RN   [10]
RP   REVIEW ON VARIANTS.
RX   PubMed=8807089; DOI=10.1006/bcmd.1996.0012;
RA   Baronciani L., Bianchi P., Zanella A.;
RT   "Hematologically important mutations: red cell pyruvate kinase.";
RL   Blood Cells Mol. Dis. 22:85-89(1996).
RN   [11]
RP   REVIEW ON VARIANTS.
RX   PubMed=9075576; DOI=10.1006/bcmd.1996.0107;
RA   Baronciani L., Bianchi P., Zanella A.;
RT   "Hematologically important mutations: red cell pyruvate kinase (1st
RT   update).";
RL   Blood Cells Mol. Dis. 22:259-264(1996).
RN   [12]
RP   REVIEW ON VARIANTS.
RX   PubMed=10087985; DOI=10.1006/bcmd.1998.0193;
RA   Baronciani L., Bianchi P., Zanella A.;
RT   "Hematologically important mutations: red cell pyruvate kinase (2nd
RT   update).";
RL   Blood Cells Mol. Dis. 24:273-279(1998).
RN   [13]
RP   REVIEW ON VARIANTS.
RX   PubMed=10772876; DOI=10.1006/bcmd.2000.0276;
RA   Bianchi P., Zanella A.;
RT   "Hematologically important mutations: red cell pyruvate kinase (third
RT   update).";
RL   Blood Cells Mol. Dis. 26:47-53(2000).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; SER-19 AND SER-26,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-43 AND SER-292, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.73 ANGSTROMS) OF 47-574 IN COMPLEX WITH
RP   SUBSTRATE ANALOG; FRUCTOSE 1,6-BISPHOSPHATE; POTASSIUM IONS AND
RP   MANGANESE IONS, ALLOSTERIC ACTIVATION, ENZYME REGULATION,
RP   CHARACTERIZATION OF VARIANTS PKRD SER-332; ASP-364; ASN-390; HIS-479;
RP   TRP-486; LEU-504 AND TRP-532, CHARACTERIZATION OF VARIANT MET-384, AND
RP   SUBUNIT.
RX   PubMed=11960989; DOI=10.1074/jbc.M202107200;
RA   Valentini G., Chiarelli L.R., Fortin R., Dolzan M., Galizzi A.,
RA   Abraham D.J., Wang C., Bianchi P., Zanella A., Mattevi A.;
RT   "Structure and function of human erythrocyte pyruvate kinase.
RT   Molecular basis of nonspherocytic hemolytic anemia.";
RL   J. Biol. Chem. 277:23807-23814(2002).
RN   [17]
RP   VARIANTS PKRD CYS-163 AND MET-384.
RX   PubMed=2018831;
RA   Neubauer B., Lakomek M., Winkler H., Parke M., Hofferbert S.,
RA   Schroter W.;
RT   "Point mutations in the L-type pyruvate kinase gene of two children
RT   with hemolytic anemia caused by pyruvate kinase deficiency.";
RL   Blood 77:1871-1875(1991).
RN   [18]
RP   VARIANT PKRD LYS-421.
RX   PubMed=1536957;
RA   Kanno H., Fujii H., Hirono A., Omine M., Miwa S.;
RT   "Identical point mutations of the R-type pyruvate kinase (PK) cDNA
RT   found in unrelated PK variants associated with hereditary hemolytic
RT   anemia.";
RL   Blood 79:1347-1350(1992).
RN   [19]
RP   VARIANT PKRD GLN-426.
RX   PubMed=8481523;
RA   Kanno H., Fujii H., Miwa S.;
RT   "Low substrate affinity of pyruvate kinase variant (PK Sapporo) caused
RT   by a single amino acid substitution (426 Arg-->Gln) associated with
RT   hereditary hemolytic anemia.";
RL   Blood 81:2439-2441(1993).
RN   [20]
RP   VARIANTS PKRD ASP-134; PRO-155; HIS-359; TRP-486; VAL-495 AND GLN-510.
RX   PubMed=8483951; DOI=10.1073/pnas.90.9.4324;
RA   Baronciani L., Beutler E.;
RT   "Analysis of pyruvate kinase-deficiency mutations that produce
RT   nonspherocytic hemolytic anemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:4324-4327(1993).
RN   [21]
RP   VARIANT PKRD HIS-479.
RX   PubMed=8161798;
RA   Kanno H., Ballas S.K., Miwa S., Fujii H., Bowman H.S.;
RT   "Molecular abnormality of erythrocyte pyruvate kinase deficiency in
RT   the Amish.";
RL   Blood 83:2311-2316(1994).
RN   [22]
RP   VARIANTS PKRD SER-332; SER-336; LYS-354 DEL; ASP-361; THR-392;
RP   HIS-498; GLN-510 AND TRP-532.
RX   PubMed=8180378;
RA   Lenzner C., Nuernberg P., Thiele B.-J., Reis A., Brabec V.,
RA   Sakalova A., Jacobasch G.;
RT   "Mutations in the pyruvate kinase L gene in patients with hereditary
RT   hemolytic anemia.";
RL   Blood 83:2817-2822(1994).
RN   [23]
RP   VARIANTS PKRD GLU-331; ALA-341; LYS-393; SER-393; ASP-458; MET-460 AND
RP   HIS-498.
RX   PubMed=7706479; DOI=10.1172/JCI117846;
RA   Baronciani L., Beutler E.;
RT   "Molecular study of pyruvate kinase deficient patients with hereditary
RT   nonspherocytic hemolytic anemia.";
RL   J. Clin. Invest. 95:1702-1709(1995).
RN   [24]
RP   VARIANTS PKRD.
RA   Baronciani L., Westwood B., Beutler E.;
RT   "Study of the molecular defects in pyruvate kinase (PK) deficient
RT   patients affected by hereditary nonspherocytic hemolytic anemia
RT   (HNHA).";
RL   J. Invest. Med. 43:341A-341A(1995).
RN   [25]
RP   VARIANT PKHYP GLU-37.
RX   PubMed=9090535;
RX   DOI=10.1002/(SICI)1098-1004(1997)9:3<282::AID-HUMU13>3.0.CO;2-Z;
RA   Beutler E., Westwood B., van Zwieten R., Roos D.;
RT   "G-to-T transition at cDNA nt 110 (K37Q) in the PKLR (pyruvate kinase)
RT   gene is the molecular basis of a case of hereditary increase of red
RT   blood cell ATP.";
RL   Hum. Mutat. 9:282-285(1997).
RN   [26]
RP   VARIANTS PKRD GLN-172; GLN-337; HIS-339; THR-357; ILE-408; THR-431;
RP   TRP-486 AND GLN-532.
RX   PubMed=9827908; DOI=10.1046/j.1365-2141.1998.01013.x;
RA   Zarza R., Alvarez R., Pujades A., Nomdedeu B., Carrera A., Estella J.,
RA   Remacha A., Sanchez J.M., Morey M., Cortes T., Perez Lungmus G.,
RA   Bureo E., Vives Corrons J.L.;
RT   "Molecular characterization of the PK-LR gene in pyruvate kinase
RT   deficient Spanish patients.";
RL   Br. J. Haematol. 103:377-382(1998).
RN   [27]
RP   VARIANT PKRD TYR-130.
RX   PubMed=9886305; DOI=10.1046/j.1365-2141.1998.01094.x;
RA   Cohen-Solal M., Prehu C., Wajcman H., Poyart C.,
RA   Bardakdjian-Michau J., Kister J., Prome D., Valentin C., Bachir D.,
RA   Galacteros F.;
RT   "A new sickle cell disease phenotype associating Hb S trait, severe
RT   pyruvate kinase deficiency (PK Conakry), and an alpha-2 globin gene
RT   variant (Hb Conakry).";
RL   Br. J. Haematol. 103:950-956(1998).
RN   [28]
RP   VARIANTS PKRD SER-332; PRO-337; TRP-486; CYS-498 AND GLN-510.
RX   PubMed=9482576;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:2<127::AID-HUMU5>3.0.CO;2-G;
RA   Pastore L., della Morte R., Frisso G., Alfinito F., Vitale D.,
RA   Calise R.M., Ferraro F., Zagari A., Rotoli B., Salvatore F.;
RT   "Novel mutations and structural implications in R-type pyruvate
RT   kinase-deficient patients from Southern Italy.";
RL   Hum. Mutat. 11:127-134(1998).
RN   [29]
RP   VARIANTS PKRD MET-335; LYS-348 DEL; GLY-387; ASP-394 AND VAL-394.
RX   PubMed=11328279; DOI=10.1046/j.1365-2141.2001.02711.x;
RA   Zanella A., Bianchi P., Fermo E., Iurlo A., Zappa M., Vercellati C.,
RA   Boschetti C., Baronciani L., Cotton F.;
RT   "Molecular characterization of the PK-LR gene in sixteen pyruvate
RT   kinase-deficient patients.";
RL   Br. J. Haematol. 113:43-48(2001).
RN   [30]
RP   VARIANTS PKRD TRP-40; 48-THR--THR-53 DEL; PRO-73; ASN-90; ARG-111;
RP   THR-154; LEU-163; VAL-165; VAL-272; ASN-310; LEU-320; GLU-358 AND
RP   PRO-374.
RX   PubMed=19085939; DOI=10.1002/humu.20915;
RA   van Wijk R., Huizinga E.G., van Wesel A.C.W., van Oirschot B.A.,
RA   Hadders M.A., van Solinge W.W.;
RT   "Fifteen novel mutations in PKLR associated with pyruvate kinase (PK)
RT   deficiency: structural implications of amino acid substitutions in
RT   PK.";
RL   Hum. Mutat. 30:446-453(2009).
RN   [31]
RP   VARIANTS PKRD ALA-341 AND GLN-569.
RX   PubMed=21794208;
RA   Lyon G.J., Jiang T., Van Wijk R., Wang W., Bodily P.M., Xing J.,
RA   Tian L., Robison R.J., Clement M., Lin Y., Zhang P., Liu Y., Moore B.,
RA   Glessner J.T., Elia J., Reimherr F., van Solinge W.W., Yandell M.,
RA   Hakonarson H., Wang J., Johnson W.E., Wei Z., Wang K.;
RT   "Exome sequencing and unrelated findings in the context of complex
RT   disease research: ethical and clinical implications.";
RL   Discov. Med. 12:41-55(2011).
CC   -!- FUNCTION: Plays a key role in glycolysis. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: ATP + pyruvate = ADP + phosphoenolpyruvate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000305|PubMed:11960989};
CC   -!- COFACTOR:
CC       Name=K(+); Xref=ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000305|PubMed:11960989};
CC   -!- ENZYME REGULATION: Allosterically activated by fructose 1,6-
CC       bisphosphate. {ECO:0000269|PubMed:11960989}.
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; pyruvate from D-
CC       glyceraldehyde 3-phosphate: step 5/5.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:11960989}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=R-type; Synonyms=PKR;
CC         IsoId=P30613-1; Sequence=Displayed;
CC       Name=L-type; Synonyms=PKL;
CC         IsoId=P30613-2; Sequence=VSP_002883;
CC   -!- DISEASE: Pyruvate kinase hyperactivity (PKHYP) [MIM:102900]:
CC       Autosomal dominant phenotype characterized by increase of red
CC       blood cell ATP. {ECO:0000269|PubMed:9090535}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Pyruvate kinase deficiency of red cells (PKRD)
CC       [MIM:266200]: A frequent cause of hereditary non-spherocytic
CC       hemolytic anemia. Clinically, pyruvate kinase-deficient patients
CC       suffer from a highly variable degree of chronic hemolysis, ranging
CC       from severe neonatal jaundice and fatal anemia at birth, severe
CC       transfusion-dependent chronic hemolysis, moderate hemolysis with
CC       exacerbation during infection, to a fully compensated hemolysis
CC       without apparent anemia. {ECO:0000269|PubMed:11328279,
CC       ECO:0000269|PubMed:11960989, ECO:0000269|PubMed:1536957,
CC       ECO:0000269|PubMed:1896471, ECO:0000269|PubMed:19085939,
CC       ECO:0000269|PubMed:2018831, ECO:0000269|PubMed:21794208,
CC       ECO:0000269|PubMed:7706479, ECO:0000269|PubMed:8161798,
CC       ECO:0000269|PubMed:8180378, ECO:0000269|PubMed:8476433,
CC       ECO:0000269|PubMed:8481523, ECO:0000269|PubMed:8483951,
CC       ECO:0000269|PubMed:9482576, ECO:0000269|PubMed:9827908,
CC       ECO:0000269|PubMed:9886305, ECO:0000269|Ref.24}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: There are 4 isozymes of pyruvate kinase in mammals:
CC       L, R, M1 and M2. L type is major isozyme in the liver, R is found
CC       in red cells, M1 is the main form in muscle, heart and brain, and
CC       M2 is found in early fetal tissues.
CC   -!- SIMILARITY: Belongs to the pyruvate kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA02515.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pklr/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Pyruvate kinase entry;
CC       URL="https://en.wikipedia.org/wiki/Pyruvate_kinase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB015983; BAA31706.1; -; mRNA.
DR   EMBL; M15465; AAA60104.1; -; mRNA.
DR   EMBL; D13243; BAA02515.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AY316591; AAP69527.1; -; Genomic_DNA.
DR   EMBL; BC025737; AAH25737.1; -; mRNA.
DR   EMBL; S60712; AAB26262.1; -; mRNA.
DR   CCDS; CCDS1109.1; -. [P30613-1]
DR   CCDS; CCDS44240.1; -. [P30613-2]
DR   PIR; I52269; KIHUPR.
DR   RefSeq; NP_000289.1; NM_000298.5. [P30613-1]
DR   RefSeq; NP_870986.1; NM_181871.3. [P30613-2]
DR   UniGene; Hs.95990; -.
DR   PDB; 2VGB; X-ray; 2.73 A; A/B/C/D=47-574.
DR   PDB; 2VGF; X-ray; 2.75 A; A/B/C/D=47-574.
DR   PDB; 2VGG; X-ray; 2.74 A; A/B/C/D=47-574.
DR   PDB; 2VGI; X-ray; 2.87 A; A/B/C/D=47-574.
DR   PDB; 4IMA; X-ray; 1.95 A; A/B/C/D=34-574.
DR   PDB; 4IP7; X-ray; 1.80 A; A/B/C/D=34-574.
DR   PDBsum; 2VGB; -.
DR   PDBsum; 2VGF; -.
DR   PDBsum; 2VGG; -.
DR   PDBsum; 2VGI; -.
DR   PDBsum; 4IMA; -.
DR   PDBsum; 4IP7; -.
DR   ProteinModelPortal; P30613; -.
DR   SMR; P30613; -.
DR   BioGrid; 111330; 15.
DR   IntAct; P30613; 6.
DR   STRING; 9606.ENSP00000339933; -.
DR   BindingDB; P30613; -.
DR   ChEMBL; CHEMBL1075126; -.
DR   DrugBank; DB02726; 2-Phosphoglycolic Acid.
DR   DrugBank; DB00119; Pyruvic acid.
DR   iPTMnet; P30613; -.
DR   PhosphoSitePlus; P30613; -.
DR   SwissPalm; P30613; -.
DR   BioMuta; PKLR; -.
DR   REPRODUCTION-2DPAGE; P30613; -.
DR   SWISS-2DPAGE; P30613; -.
DR   EPD; P30613; -.
DR   MaxQB; P30613; -.
DR   PaxDb; P30613; -.
DR   PeptideAtlas; P30613; -.
DR   PRIDE; P30613; -.
DR   DNASU; 5313; -.
DR   Ensembl; ENST00000342741; ENSP00000339933; ENSG00000143627. [P30613-1]
DR   Ensembl; ENST00000392414; ENSP00000376214; ENSG00000143627. [P30613-2]
DR   Ensembl; ENST00000571194; ENSP00000461487; ENSG00000262785. [P30613-2]
DR   Ensembl; ENST00000572740; ENSP00000459921; ENSG00000262785. [P30613-1]
DR   GeneID; 5313; -.
DR   KEGG; hsa:5313; -.
DR   UCSC; uc001fka.5; human. [P30613-1]
DR   CTD; 5313; -.
DR   DisGeNET; 5313; -.
DR   GeneCards; PKLR; -.
DR   HGNC; HGNC:9020; PKLR.
DR   HPA; CAB034376; -.
DR   HPA; CAB034378; -.
DR   HPA; HPA006653; -.
DR   MalaCards; PKLR; -.
DR   MIM; 102900; phenotype.
DR   MIM; 266200; phenotype.
DR   MIM; 609712; gene.
DR   neXtProt; NX_P30613; -.
DR   OpenTargets; ENSG00000143627; -.
DR   Orphanet; 766; Hemolytic anemia due to red cell pyruvate kinase deficiency.
DR   PharmGKB; PA33352; -.
DR   eggNOG; KOG2323; Eukaryota.
DR   eggNOG; COG0469; LUCA.
DR   GeneTree; ENSGT00390000008859; -.
DR   HOGENOM; HOG000021559; -.
DR   HOVERGEN; HBG000941; -.
DR   InParanoid; P30613; -.
DR   KO; K12406; -.
DR   OMA; PFERSED; -.
DR   OrthoDB; EOG091G0597; -.
DR   PhylomeDB; P30613; -.
DR   TreeFam; TF300390; -.
DR   BioCyc; MetaCyc:HS07088-MONOMER; -.
DR   BRENDA; 2.7.1.40; 2681.
DR   Reactome; R-HSA-163765; ChREBP activates metabolic gene expression.
DR   Reactome; R-HSA-210745; Regulation of gene expression in beta cells.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   SABIO-RK; P30613; -.
DR   UniPathway; UPA00109; UER00188.
DR   EvolutionaryTrace; P30613; -.
DR   GeneWiki; PKLR; -.
DR   GenomeRNAi; 5313; -.
DR   PMAP-CutDB; P30613; -.
DR   PRO; PR:P30613; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000143627; -.
DR   CleanEx; HS_PKLR; -.
DR   ExpressionAtlas; P30613; baseline and differential.
DR   Genevisible; P30613; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0030955; F:potassium ion binding; IEA:InterPro.
DR   GO; GO:0004743; F:pyruvate kinase activity; EXP:Reactome.
DR   GO; GO:0006754; P:ATP biosynthetic process; IEA:Ensembl.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IBA:GO_Central.
DR   GO; GO:0006096; P:glycolytic process; IBA:GO_Central.
DR   GO; GO:0042866; P:pyruvate biosynthetic process; IEA:Ensembl.
DR   GO; GO:0033198; P:response to ATP; IEA:Ensembl.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0010226; P:response to lithium ion; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   CDD; cd00288; Pyruvate_Kinase; 1.
DR   Gene3D; 3.40.1380.20; -; 1.
DR   InterPro; IPR001697; Pyr_Knase.
DR   InterPro; IPR015813; Pyrv/PenolPyrv_Kinase-like_dom.
DR   InterPro; IPR011037; Pyrv_Knase-like_insert_dom.
DR   InterPro; IPR018209; Pyrv_Knase_AS.
DR   InterPro; IPR015793; Pyrv_Knase_brl.
DR   InterPro; IPR015795; Pyrv_Knase_C.
DR   PANTHER; PTHR11817; PTHR11817; 1.
DR   Pfam; PF00224; PK; 1.
DR   Pfam; PF02887; PK_C; 1.
DR   PRINTS; PR01050; PYRUVTKNASE.
DR   SUPFAM; SSF50800; SSF50800; 1.
DR   SUPFAM; SSF51621; SSF51621; 2.
DR   SUPFAM; SSF52935; SSF52935; 1.
DR   TIGRFAMs; TIGR01064; pyruv_kin; 1.
DR   PROSITE; PS00110; PYRUVATE_KINASE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Alternative splicing;
KW   ATP-binding; Complete proteome; Disease mutation; Glycolysis;
KW   Hereditary hemolytic anemia; Kinase; Magnesium; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Potassium; Pyruvate;
KW   Reference proteome; Transferase.
FT   CHAIN         1    574       Pyruvate kinase PKLR.
FT                                /FTId=PRO_0000112094.
FT   REGION      475    480       Allosteric activator binding.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   REGION      559    564       Allosteric activator binding.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   METAL       118    118       Potassium. {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   METAL       120    120       Potassium. {ECO:0000244|PDB:2VGB,
FT                                ECO:0000269|PubMed:11960989}.
FT   METAL       156    156       Potassium. {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   METAL       157    157       Potassium; via carbonyl oxygen.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   METAL       315    315       Manganese. {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   METAL       339    339       Manganese. {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   BINDING     116    116       Substrate. {ECO:0000244|PDB:2VGB,
FT                                ECO:0000269|PubMed:11960989}.
FT   BINDING     313    313       Substrate; via amide nitrogen.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   BINDING     338    338       Substrate; via amide nitrogen.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   BINDING     339    339       Substrate; via amide nitrogen.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   BINDING     371    371       Substrate. {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   BINDING     525    525       Allosteric activator.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   BINDING     532    532       Allosteric activator.
FT                                {ECO:0000244|PDB:2VGF,
FT                                ECO:0000269|PubMed:11960989}.
FT   SITE        313    313       Transition state stabilizer.
FT                                {ECO:0000250|UniProtKB:P00549}.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      19     19       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      26     26       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      43     43       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     105    105       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     109    109       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     140    140       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P11980}.
FT   MOD_RES     148    148       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     292    292       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     313    313       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     365    365       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     365    365       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   MOD_RES     541    541       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:P52480}.
FT   VAR_SEQ       1     33       MSIQENISSLQLRSWVSKSQRDLAKSILIGAPG -> ME
FT                                (in isoform L-type). {ECO:0000305}.
FT                                /FTId=VSP_002883.
FT   VARIANT      37     37       G -> E (in PKHYP; dbSNP:rs118204087).
FT                                {ECO:0000269|PubMed:9090535}.
FT                                /FTId=VAR_011435.
FT   VARIANT      40     40       R -> W (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058467.
FT   VARIANT      48     53       Missing (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058468.
FT   VARIANT      73     73       L -> P (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058469.
FT   VARIANT      80     80       S -> P (in PKRD).
FT                                /FTId=VAR_011436.
FT   VARIANT      86     86       R -> P (in PKRD).
FT                                /FTId=VAR_011437.
FT   VARIANT      90     90       I -> N (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_011438.
FT   VARIANT      95     95       G -> R (in PKRD; dbSNP:rs750857114).
FT                                /FTId=VAR_011439.
FT   VARIANT     107    107       M -> T (in PKRD).
FT                                /FTId=VAR_004028.
FT   VARIANT     111    111       G -> R (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_011440.
FT   VARIANT     115    115       A -> P (in PKRD; Val de Marne).
FT                                /FTId=VAR_011441.
FT   VARIANT     120    120       S -> F (in PKRD; Beaujon).
FT                                /FTId=VAR_011442.
FT   VARIANT     130    130       S -> Y (in PKRD; Conakry;
FT                                dbSNP:rs118204089).
FT                                {ECO:0000269|PubMed:9886305}.
FT                                /FTId=VAR_011443.
FT   VARIANT     131    131       Missing (in PKRD).
FT                                /FTId=VAR_004029.
FT   VARIANT     134    134       V -> D (in PKRD; dbSNP:rs574051756).
FT                                {ECO:0000269|PubMed:8483951}.
FT                                /FTId=VAR_004030.
FT   VARIANT     153    153       I -> T (in PKRD).
FT                                /FTId=VAR_011474.
FT   VARIANT     154    154       A -> T (in PKRD; dbSNP:rs780192373).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058470.
FT   VARIANT     155    155       L -> P (in PKRD).
FT                                {ECO:0000269|PubMed:8483951}.
FT                                /FTId=VAR_004031.
FT   VARIANT     159    159       G -> V (in PKRD).
FT                                /FTId=VAR_011444.
FT   VARIANT     163    163       R -> C (in PKRD; Linz;
FT                                dbSNP:rs118204083).
FT                                {ECO:0000269|PubMed:2018831}.
FT                                /FTId=VAR_004033.
FT   VARIANT     163    163       R -> L (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058471.
FT   VARIANT     165    165       G -> V (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058472.
FT   VARIANT     172    172       E -> Q (in PKRD; Sassari;
FT                                dbSNP:rs757359024).
FT                                {ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004032.
FT   VARIANT     219    219       I -> T (in PKRD; dbSNP:rs200572803).
FT                                /FTId=VAR_011475.
FT   VARIANT     221    221       D -> DD (in PKRD).
FT                                /FTId=VAR_004034.
FT   VARIANT     222    222       G -> A (in PKRD; Katsushika).
FT                                /FTId=VAR_011445.
FT   VARIANT     263    263       G -> R (in PKRD).
FT                                /FTId=VAR_011447.
FT   VARIANT     263    263       G -> W (in PKRD).
FT                                /FTId=VAR_011448.
FT   VARIANT     272    272       L -> V (in PKRD; dbSNP:rs147659527).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058473.
FT   VARIANT     275    275       G -> R (in PKRD; dbSNP:rs747549978).
FT                                /FTId=VAR_004035.
FT   VARIANT     281    281       D -> N (in PKRD).
FT                                /FTId=VAR_004036.
FT   VARIANT     287    287       F -> V (in PKRD).
FT                                /FTId=VAR_004037.
FT   VARIANT     288    288       V -> L (in PKRD; Moriguchi).
FT                                /FTId=VAR_011449.
FT   VARIANT     293    293       D -> N (in PKRD).
FT                                /FTId=VAR_011446.
FT   VARIANT     295    295       A -> V (in PKRD; dbSNP:rs766353400).
FT                                /FTId=VAR_011450.
FT   VARIANT     310    310       I -> N (in PKRD; Dordrecht).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_011451.
FT   VARIANT     314    314       I -> T (in PKRD; Hong Kong).
FT                                /FTId=VAR_004038.
FT   VARIANT     315    315       E -> K (in PKRD).
FT                                /FTId=VAR_011452.
FT   VARIANT     320    320       V -> L (in PKRD; dbSNP:rs549295725).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058474.
FT   VARIANT     331    331       D -> E (in PKRD; Parma;
FT                                dbSNP:rs138476691).
FT                                {ECO:0000269|PubMed:7706479}.
FT                                /FTId=VAR_004039.
FT   VARIANT     331    331       D -> N (in PKRD; dbSNP:rs773893686).
FT                                /FTId=VAR_011453.
FT   VARIANT     332    332       G -> S (in PKRD; loss of catalytical
FT                                activity; dbSNP:rs773626254).
FT                                {ECO:0000269|PubMed:11960989,
FT                                ECO:0000269|PubMed:8180378,
FT                                ECO:0000269|PubMed:9482576}.
FT                                /FTId=VAR_004040.
FT   VARIANT     335    335       V -> M (in PKRD).
FT                                {ECO:0000269|PubMed:11328279}.
FT                                /FTId=VAR_011476.
FT   VARIANT     336    336       A -> S (in PKRD).
FT                                {ECO:0000269|PubMed:8180378}.
FT                                /FTId=VAR_004041.
FT   VARIANT     337    337       R -> P (in PKRD).
FT                                {ECO:0000269|PubMed:9482576}.
FT                                /FTId=VAR_004042.
FT   VARIANT     337    337       R -> Q (in PKRD).
FT                                {ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004043.
FT   VARIANT     339    339       D -> H (in PKRD).
FT                                {ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004044.
FT   VARIANT     341    341       G -> A (in PKRD).
FT                                {ECO:0000269|PubMed:21794208,
FT                                ECO:0000269|PubMed:7706479}.
FT                                /FTId=VAR_004045.
FT   VARIANT     341    341       G -> D (in PKRD).
FT                                /FTId=VAR_011454.
FT   VARIANT     342    342       I -> F (in PKRD).
FT                                /FTId=VAR_011455.
FT   VARIANT     348    348       K -> N (in PKRD; Kamata).
FT                                /FTId=VAR_011456.
FT   VARIANT     348    348       Missing (in PKRD; Brescia).
FT                                {ECO:0000269|PubMed:11328279}.
FT                                /FTId=VAR_011457.
FT   VARIANT     352    352       A -> D (in PKRD).
FT                                /FTId=VAR_011477.
FT   VARIANT     354    354       Missing (in PKRD).
FT                                {ECO:0000269|PubMed:8180378}.
FT                                /FTId=VAR_004046.
FT   VARIANT     357    357       I -> T (in PKRD; dbSNP:rs779152555).
FT                                {ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004047.
FT   VARIANT     358    358       G -> E (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058475.
FT   VARIANT     359    359       R -> C (in PKRD; Aomori;
FT                                dbSNP:rs138871700).
FT                                /FTId=VAR_004048.
FT   VARIANT     359    359       R -> H (in PKRD).
FT                                {ECO:0000269|PubMed:8483951}.
FT                                /FTId=VAR_004049.
FT   VARIANT     361    361       N -> D (in PKRD; dbSNP:rs765903674).
FT                                {ECO:0000269|PubMed:8180378}.
FT                                /FTId=VAR_004050.
FT   VARIANT     364    364       G -> D (in PKRD; Tjaereborg; unstability
FT                                of the protein and decrease in catalytic
FT                                activity). {ECO:0000269|PubMed:11960989}.
FT                                /FTId=VAR_011458.
FT   VARIANT     368    368       V -> F (in PKRD; Osaka).
FT                                {ECO:0000269|PubMed:8476433}.
FT                                /FTId=VAR_004051.
FT   VARIANT     374    374       L -> P (in PKRD).
FT                                {ECO:0000269|PubMed:19085939}.
FT                                /FTId=VAR_058476.
FT   VARIANT     376    376       S -> I (in PKRD).
FT                                /FTId=VAR_011459.
FT   VARIANT     384    384       T -> M (in PKRD; Tokyo/Beirut; most
FT                                common mutation in Japanese population;
FT                                no conformational change;
FT                                dbSNP:rs74315362).
FT                                {ECO:0000269|PubMed:11960989,
FT                                ECO:0000269|PubMed:1896471,
FT                                ECO:0000269|PubMed:2018831}.
FT                                /FTId=VAR_004052.
FT   VARIANT     385    385       R -> W (in PKRD).
FT                                /FTId=VAR_011478.
FT   VARIANT     387    387       E -> G (in PKRD).
FT                                {ECO:0000269|PubMed:11328279}.
FT                                /FTId=VAR_011460.
FT   VARIANT     390    390       D -> N (in PKRD; Mantova; almost complete
FT                                inactivation; dbSNP:rs147034239).
FT                                {ECO:0000269|PubMed:11960989}.
FT                                /FTId=VAR_011461.
FT   VARIANT     392    392       A -> T (in PKRD).
FT                                {ECO:0000269|PubMed:8180378}.
FT                                /FTId=VAR_004053.
FT   VARIANT     393    393       N -> K (in PKRD).
FT                                {ECO:0000269|PubMed:7706479}.
FT                                /FTId=VAR_004054.
FT   VARIANT     393    393       N -> S (in PKRD; Paris;
FT                                dbSNP:rs776594413).
FT                                {ECO:0000269|PubMed:7706479}.
FT                                /FTId=VAR_004055.
FT   VARIANT     394    394       A -> D (in PKRD).
FT                                {ECO:0000269|PubMed:11328279}.
FT                                /FTId=VAR_011462.
FT   VARIANT     394    394       A -> V (in PKRD).
FT                                {ECO:0000269|PubMed:11328279}.
FT                                /FTId=VAR_011463.
FT   VARIANT     401    401       C -> CS (in PKRD).
FT                                /FTId=VAR_004056.
FT   VARIANT     408    408       T -> A (in PKRD; Hirosaki).
FT                                /FTId=VAR_011464.
FT   VARIANT     408    408       T -> I (in PKRD).
FT                                {ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004057.
FT   VARIANT     421    421       Q -> K (in PKRD; Fukushima/Maebashi/
FT                                Sendai; dbSNP:rs118204084).
FT                                {ECO:0000269|PubMed:1536957}.
FT                                /FTId=VAR_004058.
FT   VARIANT     426    426       R -> Q (in PKRD; Sapporo;
FT                                dbSNP:rs768002493).
FT                                {ECO:0000269|PubMed:8481523}.
FT                                /FTId=VAR_004059.
FT   VARIANT     426    426       R -> W (in PKRD; Naniwa).
FT                                /FTId=VAR_004060.
FT   VARIANT     427    427       E -> A (in PKRD).
FT                                /FTId=VAR_011465.
FT   VARIANT     427    427       E -> D (in PKRD).
FT                                /FTId=VAR_011466.
FT   VARIANT     431    431       A -> T (in PKRD; dbSNP:rs762591322).
FT                                {ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004061.
FT   VARIANT     458    458       G -> D (in PKRD; dbSNP:rs755522396).
FT                                {ECO:0000269|PubMed:7706479}.
FT                                /FTId=VAR_004062.
FT   VARIANT     459    459       A -> V (in PKRD).
FT                                /FTId=VAR_004063.
FT   VARIANT     460    460       V -> M (in PKRD; dbSNP:rs752034960).
FT                                {ECO:0000269|PubMed:7706479}.
FT                                /FTId=VAR_004064.
FT   VARIANT     468    468       A -> G (in PKRD; dbSNP:rs750540943).
FT                                /FTId=VAR_011479.
FT   VARIANT     468    468       A -> V (in PKRD; Hadano).
FT                                /FTId=VAR_004065.
FT   VARIANT     477    477       T -> A (in PKRD; dbSNP:rs759466273).
FT                                /FTId=VAR_011467.
FT   VARIANT     479    479       R -> H (in PKRD; Amish; no conformational
FT                                change; dbSNP:rs118204085).
FT                                {ECO:0000269|PubMed:11960989,
FT                                ECO:0000269|PubMed:8161798}.
FT                                /FTId=VAR_011480.
FT   VARIANT     485    485       S -> F (in PKRD).
FT                                /FTId=VAR_011468.
FT   VARIANT     486    486       R -> W (in PKRD; frequent mutation; no
FT                                conformational change;
FT                                dbSNP:rs116100695).
FT                                {ECO:0000269|PubMed:11960989,
FT                                ECO:0000269|PubMed:8483951,
FT                                ECO:0000269|PubMed:9482576,
FT                                ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004066.
FT   VARIANT     488    488       R -> Q (in PKRD; dbSNP:rs369183199).
FT                                /FTId=VAR_011469.
FT   VARIANT     490    490       R -> W (in PKRD; dbSNP:rs200133000).
FT                                /FTId=VAR_004067.
FT   VARIANT     495    495       A -> T (in PKRD).
FT                                /FTId=VAR_011470.
FT   VARIANT     495    495       A -> V (in PKRD; dbSNP:rs141560532).
FT                                {ECO:0000269|PubMed:8483951}.
FT                                /FTId=VAR_004068.
FT   VARIANT     498    498       R -> C (in PKRD; dbSNP:rs551883218).
FT                                {ECO:0000269|PubMed:9482576}.
FT                                /FTId=VAR_004069.
FT   VARIANT     498    498       R -> H (in PKRD; dbSNP:rs758327704).
FT                                {ECO:0000269|PubMed:7706479,
FT                                ECO:0000269|PubMed:8180378}.
FT                                /FTId=VAR_004070.
FT   VARIANT     504    504       R -> L (in PKRD; instability of the
FT                                protein; dbSNP:rs185753709).
FT                                {ECO:0000269|PubMed:11960989}.
FT                                /FTId=VAR_011471.
FT   VARIANT     506    506       V -> I (in dbSNP:rs8177988).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_018848.
FT   VARIANT     510    510       R -> Q (in PKRD; the most common mutation
FT                                in European population;
FT                                dbSNP:rs113403872).
FT                                {ECO:0000269|PubMed:8180378,
FT                                ECO:0000269|PubMed:8483951,
FT                                ECO:0000269|PubMed:9482576}.
FT                                /FTId=VAR_004071.
FT   VARIANT     511    511       G -> R (in PKRD).
FT                                /FTId=VAR_011472.
FT   VARIANT     531    531       R -> C (in PKRD).
FT                                /FTId=VAR_011473.
FT   VARIANT     532    532       R -> Q (in PKRD; dbSNP:rs758278200).
FT                                {ECO:0000269|PubMed:9827908}.
FT                                /FTId=VAR_004072.
FT   VARIANT     532    532       R -> W (in PKRD; Complete loss in the
FT                                responsiveness to fructose 1,6-
FT                                bisphosphate, FBP; dbSNP:rs201255024).
FT                                {ECO:0000269|PubMed:11960989,
FT                                ECO:0000269|PubMed:8180378}.
FT                                /FTId=VAR_004073.
FT   VARIANT     552    552       V -> M (in PKRD; dbSNP:rs370316462).
FT                                /FTId=VAR_004074.
FT   VARIANT     557    557       G -> A (in PKRD).
FT                                /FTId=VAR_011481.
FT   VARIANT     559    559       R -> G (in PKRD).
FT                                /FTId=VAR_004075.
FT   VARIANT     566    566       N -> K (in PKRD).
FT                                /FTId=VAR_004076.
FT   VARIANT     569    569       R -> Q (in PKRD; dbSNP:rs61755431).
FT                                {ECO:0000269|PubMed:21794208}.
FT                                /FTId=VAR_011482.
FT   CONFLICT    381    381       P -> A (in Ref. 3; BAA02515).
FT                                {ECO:0000305}.
FT   CONFLICT    423    423       A -> R (in Ref. 2; AAA60104).
FT                                {ECO:0000305}.
FT   TURN         49     51       {ECO:0000244|PDB:4IMA}.
FT   HELIX        55     57       {ECO:0000244|PDB:4IMA}.
FT   HELIX        61     64       {ECO:0000244|PDB:4IP7}.
FT   HELIX        69     74       {ECO:0000244|PDB:4IP7}.
FT   STRAND       88     93       {ECO:0000244|PDB:4IP7}.
FT   TURN         96     98       {ECO:0000244|PDB:4IP7}.
FT   HELIX       101    110       {ECO:0000244|PDB:4IP7}.
FT   STRAND      112    118       {ECO:0000244|PDB:4IP7}.
FT   HELIX       124    139       {ECO:0000244|PDB:4IP7}.
FT   TURN        140    143       {ECO:0000244|PDB:2VGB}.
FT   HELIX       145    147       {ECO:0000244|PDB:4IP7}.
FT   STRAND      152    156       {ECO:0000244|PDB:4IP7}.
FT   STRAND      162    164       {ECO:0000244|PDB:4IP7}.
FT   STRAND      170    172       {ECO:0000244|PDB:2VGB}.
FT   STRAND      175    177       {ECO:0000244|PDB:4IP7}.
FT   STRAND      182    186       {ECO:0000244|PDB:4IP7}.
FT   HELIX       189    191       {ECO:0000244|PDB:4IP7}.
FT   STRAND      199    203       {ECO:0000244|PDB:4IP7}.
FT   HELIX       207    210       {ECO:0000244|PDB:4IP7}.
FT   STRAND      216    219       {ECO:0000244|PDB:4IP7}.
FT   TURN        220    223       {ECO:0000244|PDB:4IP7}.
FT   STRAND      224    232       {ECO:0000244|PDB:4IP7}.
FT   STRAND      235    242       {ECO:0000244|PDB:4IP7}.
FT   STRAND      244    246       {ECO:0000244|PDB:4IP7}.
FT   STRAND      251    253       {ECO:0000244|PDB:4IP7}.
FT   HELIX       266    277       {ECO:0000244|PDB:4IP7}.
FT   STRAND      281    285       {ECO:0000244|PDB:4IP7}.
FT   HELIX       291    301       {ECO:0000244|PDB:4IP7}.
FT   HELIX       303    305       {ECO:0000244|PDB:4IP7}.
FT   STRAND      309    314       {ECO:0000244|PDB:4IP7}.
FT   HELIX       317    321       {ECO:0000244|PDB:4IP7}.
FT   HELIX       323    329       {ECO:0000244|PDB:4IP7}.
FT   STRAND      330    336       {ECO:0000244|PDB:4IP7}.
FT   HELIX       337    343       {ECO:0000244|PDB:4IP7}.
FT   HELIX       346    348       {ECO:0000244|PDB:4IP7}.
FT   HELIX       349    363       {ECO:0000244|PDB:4IP7}.
FT   STRAND      367    372       {ECO:0000244|PDB:4IP7}.
FT   HELIX       375    378       {ECO:0000244|PDB:4IP7}.
FT   HELIX       385    397       {ECO:0000244|PDB:4IP7}.
FT   STRAND      400    405       {ECO:0000244|PDB:4IP7}.
FT   HELIX       406    409       {ECO:0000244|PDB:4IP7}.
FT   HELIX       414    430       {ECO:0000244|PDB:4IP7}.
FT   HELIX       434    442       {ECO:0000244|PDB:4IP7}.
FT   HELIX       451    466       {ECO:0000244|PDB:4IP7}.
FT   STRAND      469    474       {ECO:0000244|PDB:4IP7}.
FT   STRAND      476    478       {ECO:0000244|PDB:4IP7}.
FT   HELIX       479    485       {ECO:0000244|PDB:4IP7}.
FT   STRAND      490    498       {ECO:0000244|PDB:4IP7}.
FT   HELIX       500    505       {ECO:0000244|PDB:4IP7}.
FT   HELIX       506    508       {ECO:0000244|PDB:4IP7}.
FT   STRAND      512    516       {ECO:0000244|PDB:4IP7}.
FT   HELIX       525    542       {ECO:0000244|PDB:4IP7}.
FT   STRAND      551    561       {ECO:0000244|PDB:4IP7}.
FT   STRAND      565    572       {ECO:0000244|PDB:4IP7}.
SQ   SEQUENCE   574 AA;  61830 MW;  3B430896832032F5 CRC64;
     MSIQENISSL QLRSWVSKSQ RDLAKSILIG APGGPAGYLR RASVAQLTQE LGTAFFQQQQ
     LPAAMADTFL EHLCLLDIDS EPVAARSTSI IATIGPASRS VERLKEMIKA GMNIARLNFS
     HGSHEYHAES IANVREAVES FAGSPLSYRP VAIALDTKGP EIRTGILQGG PESEVELVKG
     SQVLVTVDPA FRTRGNANTV WVDYPNIVRV VPVGGRIYID DGLISLVVQK IGPEGLVTQV
     ENGGVLGSRK GVNLPGAQVD LPGLSEQDVR DLRFGVEHGV DIVFASFVRK ASDVAAVRAA
     LGPEGHGIKI ISKIENHEGV KRFDEILEVS DGIMVARGDL GIEIPAEKVF LAQKMMIGRC
     NLAGKPVVCA TQMLESMITK PRPTRAETSD VANAVLDGAD CIMLSGETAK GNFPVEAVKM
     QHAIAREAEA AVYHRQLFEE LRRAAPLSRD PTEVTAIGAV EAAFKCCAAA IIVLTTTGRS
     AQLLSRYRPR AAVIAVTRSA QAARQVHLCR GVFPLLYREP PEAIWADDVD RRVQFGIESG
     KLRGFLRVGD LVIVVTGWRP GSGYTNIMRV LSIS
//
